CN1309418C - 免疫刺激性寡脱氧核苷酸 - Google Patents
免疫刺激性寡脱氧核苷酸 Download PDFInfo
- Publication number
- CN1309418C CN1309418C CNB018107974A CN01810797A CN1309418C CN 1309418 C CN1309418 C CN 1309418C CN B018107974 A CNB018107974 A CN B018107974A CN 01810797 A CN01810797 A CN 01810797A CN 1309418 C CN1309418 C CN 1309418C
- Authority
- CN
- China
- Prior art keywords
- phosphoric acid
- monothio
- pharmaceutical composition
- hhh
- desoxyribose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0100000A AT410173B (de) | 2000-06-08 | 2000-06-08 | Antigene zusammensetzung |
| ATA1000/2000 | 2000-06-08 | ||
| AT19732000 | 2000-11-23 | ||
| ATA1973/2000 | 2000-11-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1434723A CN1434723A (zh) | 2003-08-06 |
| CN1309418C true CN1309418C (zh) | 2007-04-11 |
Family
ID=25608484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB018107974A Expired - Lifetime CN1309418C (zh) | 2000-06-08 | 2001-06-07 | 免疫刺激性寡脱氧核苷酸 |
Country Status (25)
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| WO2001051500A1 (en) | 2000-01-14 | 2001-07-19 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| HU228264B1 (en) * | 2000-06-08 | 2013-02-28 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
| WO2002069369A2 (en) * | 2000-12-08 | 2002-09-06 | Coley Pharmaceutical Gmbh | Cpg-like nucleic acids and methods of use thereof |
| EP1347775B1 (en) | 2001-01-05 | 2016-11-30 | Valneva Austria GmbH | Uses for polycationic compounds as vaccine adjuvants |
| US20040081655A1 (en) * | 2001-01-05 | 2004-04-29 | Karen Lingnau | Methods and compositions comprising polycationic compounds |
| WO2002053184A2 (en) * | 2001-01-05 | 2002-07-11 | Intercell Ag | Uses for polycationic compounds as vaccine adjuvants |
| WO2002053185A2 (en) * | 2001-01-05 | 2002-07-11 | Intercell Ag | Anti-inflammatory use of polycationic compounds |
| AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| EP1390494A2 (en) * | 2001-05-21 | 2004-02-25 | Intercell AG | Method for stabilising of nucleic acids |
| EP1412390A2 (en) * | 2001-07-26 | 2004-04-28 | Tanox, Inc. | Agents that activate or inhibit toll-like receptor 9 |
| US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
| US7354909B2 (en) * | 2001-08-14 | 2008-04-08 | The United States Of America As Represented By Secretary Of The Department Of Health And Human Services | Method for rapid generation of mature dendritic cells |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| US20050250716A1 (en) * | 2001-12-07 | 2005-11-10 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
| AU2002366710A1 (en) | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
| US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
| US8088388B2 (en) | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
| CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
| JP2005533855A (ja) | 2002-07-24 | 2005-11-10 | インターツェル・アクチェンゲゼルシャフト | 病原性ウイルスからの別のリーディングフレームによりコードされる抗原 |
| AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
| US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
| EP1537418A2 (en) | 2002-09-13 | 2005-06-08 | Intercell AG | Method for isolating hepatitis c virus peptides |
| US8263091B2 (en) | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
| JP5116971B2 (ja) | 2002-10-15 | 2013-01-09 | インターセル アーゲー | B群連鎖球菌の接着因子をコードする核酸、b群連鎖球菌の接着因子、およびその使用 |
| CN1756843B (zh) | 2003-03-04 | 2012-03-21 | 英特塞尔股份公司 | 化脓链球菌抗原 |
| ES2351489T3 (es) * | 2003-03-24 | 2011-02-07 | Intercell Ag | Vacunas mejoradas. |
| AU2004224746B2 (en) | 2003-03-24 | 2009-04-23 | Valneva Austria Gmbh | Improved vaccines |
| AU2004226262A1 (en) | 2003-03-31 | 2004-10-14 | Intercell Ag | Staphylococcus epidermidis antigens |
| US7635487B2 (en) | 2003-04-15 | 2009-12-22 | Intercell Ag | S. pneumoniae antigens |
| EP1620460A2 (en) | 2003-05-07 | 2006-02-01 | Intercell AG | Streptococcus agalactiae antigens i + ii |
| EP1629005A2 (en) | 2003-05-30 | 2006-03-01 | Intercell AG | Enterococcus antigens |
| CA2530062A1 (en) * | 2003-07-11 | 2005-01-20 | Intercell Ag | Hcv vaccines |
| JP4817599B2 (ja) * | 2003-12-25 | 2011-11-16 | 独立行政法人科学技術振興機構 | 免疫活性増強剤とこれを用いた免疫活性の増強方法 |
| KR100721928B1 (ko) * | 2004-11-05 | 2007-05-28 | 주식회사 바이오씨에스 | CpG 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물 |
| DK1931379T3 (da) | 2005-10-07 | 2013-08-19 | Sec Dep For Health | Proteiner med forbedret opløselighed samt fremgangsmåder til frembringelse og anvendelse af samme |
| TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
| KR20090024292A (ko) | 2006-06-28 | 2009-03-06 | 스태튼스 세룸 인스티튜트 | 단백질 단편 또는 펩타이드 혼합물로서 전달되는 항원을 가진 백신접종에 의해 준우성 항원결정기를 포함하는 t세포 레퍼토리 확장 |
| EP2292647A3 (en) | 2006-07-07 | 2011-06-08 | Intercell AG | Small Streptococcus pyogenes antigens and their use |
| EP2289906A1 (en) | 2006-09-15 | 2011-03-02 | Intercell AG | Borrelia antigens |
| EP1923069A1 (en) | 2006-11-20 | 2008-05-21 | Intercell AG | Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| EP2266592A3 (en) | 2007-01-12 | 2012-08-08 | Intercell AG | Protective proteins of S. agalactiae, combinations thereof and methods of using the same |
| CA2685805A1 (en) | 2007-05-02 | 2008-11-13 | Intercell Ag | Klebsiella antigens |
| EP2012122A1 (en) | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
| EP2158211B1 (en) | 2007-05-31 | 2016-08-10 | Medigene AG | Mutated structural protein of a parvovirus |
| EP2511291A3 (en) | 2007-06-18 | 2012-11-07 | Intercell AG | Chlamydia antigens |
| AU2009226949A1 (en) | 2008-03-17 | 2009-09-24 | Intercell Ag | Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto |
| WO2009155484A2 (en) | 2008-06-20 | 2009-12-23 | Wyeth | Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains |
| EP2424882A2 (en) | 2009-02-05 | 2012-03-07 | Intercell AG | Peptides protective against e. faecalis, methods and uses relating thereto |
| EP2405938A2 (en) | 2009-02-13 | 2012-01-18 | Intercell AG | Nontypable haemophilus influenzae antigens |
| AU2010264538B2 (en) | 2009-06-22 | 2013-10-03 | Wyeth Llc | Immunogenic compositions of Staphylococcus aureus antigens |
| WO2011041003A2 (en) | 2009-06-22 | 2011-04-07 | Wyeth Llc | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
| AU2010288239B2 (en) | 2009-08-27 | 2014-01-16 | Novartis Ag | Adjuvant comprising aluminium, oligonucleotide and polycation |
| EP2319871A1 (en) | 2009-11-05 | 2011-05-11 | Sanofi-aventis | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
| PH12012500564A1 (en) | 2009-10-09 | 2012-10-22 | Sanofi Sa | Polypeptides for binding to the receptor for advanced glycation endproducts as well as compositions and methods involving the same |
| EP2308896A1 (en) | 2009-10-09 | 2011-04-13 | Sanofi-aventis | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
| US8765148B2 (en) | 2010-02-19 | 2014-07-01 | Valneva Austria Gmbh | 1C31 nanoparticles |
| WO2012020326A1 (en) | 2010-03-18 | 2012-02-16 | Novartis Ag | Adjuvanted vaccines for serogroup b meningococcus |
| EP3626263A1 (en) | 2010-06-04 | 2020-03-25 | Wyeth LLC | Vaccine formulations |
| CA2808975C (en) | 2010-08-23 | 2018-10-30 | Wyeth Llc | Stable formulations of neisseria meningitidis rlp2086 antigens |
| KR101907434B1 (ko) | 2010-09-03 | 2018-10-12 | 발네바 오스트리아 게엠베하 | C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도 |
| AR082925A1 (es) | 2010-09-08 | 2013-01-16 | Medigene Ag | Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados |
| KR101584871B1 (ko) | 2010-09-10 | 2016-01-22 | 와이어쓰 엘엘씨 | 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체 |
| HUE033072T2 (hu) | 2010-12-22 | 2017-11-28 | Wyeth Llc | Staphylococcus aureus antigének immunogén készítményei |
| JP5872684B2 (ja) * | 2011-05-26 | 2016-03-01 | インターベット インターナショナル ベー. フェー. | 免疫刺激性オリゴデオキシヌクレオチド |
| US9315814B2 (en) * | 2011-05-26 | 2016-04-19 | Intervet Inc. | Immunostimulatory oligodeoxynucleotides |
| ITMI20111182A1 (it) | 2011-06-28 | 2012-12-29 | Canio Buonavoglia | Vaccino per coronavirus canino |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| CA2865745C (en) | 2012-03-09 | 2018-01-09 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| RU2672053C2 (ru) | 2012-12-20 | 2018-11-09 | Пфайзер Инк. | Способ гликоконъюгации |
| CA2903716C (en) | 2013-03-08 | 2019-04-09 | Pfizer Inc. | Immunogenic fusion polypeptides |
| RU2662968C2 (ru) | 2013-09-08 | 2018-07-31 | Пфайзер Инк. | Иммуногенная композиция против neisseria meningitidis (варианты) |
| WO2016130569A1 (en) | 2015-02-09 | 2016-08-18 | Mj Biologics, Inc. | A composition comprising pedv antigens and methods for making and using the composition |
| CN106488929B (zh) * | 2014-05-09 | 2021-08-24 | 乌得勒支大学控股有限公司 | 新型cath2衍生物 |
| KR20190049940A (ko) | 2015-02-19 | 2019-05-09 | 화이자 인코포레이티드 | 나이세리아 메닌지티디스 조성물 및 그의 방법 |
| KR102143534B1 (ko) | 2015-05-04 | 2020-08-12 | 화이자 인코포레이티드 | B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도 |
| US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| SG11201906519RA (en) | 2017-01-31 | 2019-08-27 | Pfizer | Neisseria meningitidis compositions and methods thereof |
| EP3527223A1 (en) | 2018-02-16 | 2019-08-21 | 2A Pharma AB | Mutated parvovirus structural protein |
| CN112074295A (zh) | 2018-02-16 | 2020-12-11 | 2A制药公司 | 用于治疗自身免疫性疾病的细小病毒结构蛋白 |
| KR20220010478A (ko) | 2019-05-20 | 2022-01-25 | 발네바 에스이 | 기도 감염의 치료 또는 예방용 서브유닛 백신 |
| WO2020240268A1 (en) | 2019-05-31 | 2020-12-03 | Universidad De Chile | An immunogenic formulation that induces protection against shiga toxin-producing escherichia coli (stec) |
| CA3155669A1 (en) | 2019-09-27 | 2021-04-01 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| WO2021211279A1 (en) | 2020-04-17 | 2021-10-21 | Regents Of The University Of Minnesota | SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF |
| EP4203995A1 (en) | 2020-08-26 | 2023-07-05 | Pfizer Inc. | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| WO2022074061A1 (en) | 2020-10-07 | 2022-04-14 | Valneva Sweden Ab | Cholera vaccine formulation |
| WO2023083964A1 (en) | 2021-11-11 | 2023-05-19 | 2A Pharma Ab | Parvovirus structural protein against beta- and gamma-hpv |
| WO2023232901A1 (en) | 2022-06-01 | 2023-12-07 | Valneva Austria Gmbh | Clostridium difficile vaccine |
| KR20250054810A (ko) | 2022-09-29 | 2025-04-23 | 화이자 인코포레이티드 | Rsv f 단백질 삼량체를 포함하는 면역원성 조성물 |
| WO2026038177A1 (en) | 2024-08-16 | 2026-02-19 | Pfizer Inc. | Immunogenic compositions and uses thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3906092A (en) * | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
| WO1990014424A1 (en) * | 1989-05-16 | 1990-11-29 | Scripps Clinic And Research Foundation | Method for isolating receptors having a preselected specificity |
| WO1992011389A1 (en) * | 1990-12-21 | 1992-07-09 | F. Hoffmann-La Roche Ag | Hla dqbeta dna typing |
| US5691136A (en) * | 1991-10-23 | 1997-11-25 | Baylor College Of Medicine | Fingerprinting bacterial strains using repetitive DNA sequence amplification |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3725545A (en) | 1971-02-03 | 1973-04-03 | R Maes | Enhancement of antibody production by nucleic acid-polycation complexes |
| ZA908001B (en) * | 1989-10-11 | 1991-08-28 | Merrell Dow Pharma | Inosine/guanosine derivatives as immunosuppressive agents |
| US5514577A (en) * | 1990-02-26 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide therapies for modulating the effects of herpes viruses |
| US5098437A (en) * | 1991-02-13 | 1992-03-24 | Pfizer Hospital Products Group, Inc. | Acetabular cup positioning insert |
| US5646262A (en) * | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
| US20020081577A1 (en) * | 1995-06-06 | 2002-06-27 | Robert L. Kilkuskie | Oligonucleotides speciific for hepatitis c virus |
| ZA964446B (en) * | 1995-06-06 | 1996-12-06 | Hoffmann La Roche | Oligonucleotides specific for hepatitis c virus |
| ES2168472T3 (es) * | 1995-06-06 | 2002-06-16 | Beth Israel Hospital | Procedimiento y aparato para ensayo diagnostico de adn. |
| AU736785B2 (en) * | 1996-10-02 | 2001-08-02 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Detection and identification of non-polio enteroviruses |
| WO1998016247A1 (en) * | 1996-10-11 | 1998-04-23 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| WO1998055609A1 (en) | 1997-06-06 | 1998-12-10 | The Regents Of The University Of California | Inhibitors of dna immunostimulatory sequence activity |
| US5955443A (en) * | 1998-03-19 | 1999-09-21 | Isis Pharmaceuticals Inc. | Antisense modulation of PECAM-1 |
| US6001651A (en) * | 1998-03-20 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense modulation of LFA-3 |
| IL126919A0 (en) * | 1998-11-05 | 1999-09-22 | Univ Ben Gurion | Antisense oligomer |
| AU765940B2 (en) * | 1998-06-24 | 2003-10-02 | Innogenetics N.V. | Particles of HCV envelope proteins: use for vaccination |
| WO2001022972A2 (en) | 1999-09-25 | 2001-04-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
| AU2001257366B2 (en) | 2000-05-01 | 2006-03-16 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| AT410173B (de) * | 2000-06-08 | 2003-02-25 | Cistem Biotechnologies Gmbh | Antigene zusammensetzung |
| HU228264B1 (en) * | 2000-06-08 | 2013-02-28 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
| AU2004224746B2 (en) * | 2003-03-24 | 2009-04-23 | Valneva Austria Gmbh | Improved vaccines |
| US7951845B2 (en) * | 2006-01-19 | 2011-05-31 | The Regents Of The University Of Michigan | Composition and method of treating hearing loss |
-
2001
- 2001-06-07 HU HU0301229A patent/HU228264B1/hu unknown
- 2001-06-07 SK SK1815-2002A patent/SK287689B6/sk not_active IP Right Cessation
- 2001-06-07 AU AU8181201A patent/AU8181201A/xx active Pending
- 2001-06-07 IL IL15295901A patent/IL152959A0/xx active IP Right Grant
- 2001-06-07 EP EP20010960277 patent/EP1296713B1/en not_active Expired - Lifetime
- 2001-06-07 PL PL358982A patent/PL211036B1/pl unknown
- 2001-06-07 CN CNB018107974A patent/CN1309418C/zh not_active Expired - Lifetime
- 2001-06-07 ES ES01960277T patent/ES2206424T3/es not_active Expired - Lifetime
- 2001-06-07 CA CA2411575A patent/CA2411575C/en not_active Expired - Lifetime
- 2001-06-07 AU AU2001281812A patent/AU2001281812B2/en not_active Expired
- 2001-06-07 AT AT01960277T patent/ATE249839T1/de active
- 2001-06-07 US US10/297,555 patent/US8568742B2/en active Active
- 2001-06-07 BR BRPI0111639A patent/BRPI0111639B8/pt not_active IP Right Cessation
- 2001-06-07 SI SI200130047T patent/SI1296713T1/xx unknown
- 2001-06-07 WO PCT/EP2001/006433 patent/WO2001093905A1/en not_active Ceased
- 2001-06-07 CZ CZ2002-4168A patent/CZ304195B6/cs not_active IP Right Cessation
- 2001-06-07 DK DK01960277T patent/DK1296713T3/da active
- 2001-06-07 JP JP2002501476A patent/JP5271471B2/ja not_active Expired - Lifetime
- 2001-06-07 KR KR20027016711A patent/KR100799788B1/ko not_active Expired - Lifetime
- 2001-06-07 PT PT01960277T patent/PT1296713E/pt unknown
- 2001-06-07 RU RU2003100409A patent/RU2293573C2/ru active
- 2001-06-07 DE DE2001600814 patent/DE60100814T2/de not_active Expired - Lifetime
- 2001-06-07 RU RU2007103151A patent/RU2413520C2/ru active
- 2001-06-07 MX MXPA02012010A patent/MXPA02012010A/es active IP Right Grant
- 2001-06-07 TR TR200302015T patent/TR200302015T4/xx unknown
-
2002
- 2002-11-18 IS IS6627A patent/IS1993B/is unknown
- 2002-11-20 IL IL152959A patent/IL152959A/en unknown
- 2002-12-04 NO NO20025835A patent/NO329492B1/no not_active IP Right Cessation
-
2013
- 2013-01-10 JP JP2013002571A patent/JP5908851B2/ja not_active Expired - Lifetime
- 2013-03-06 US US13/786,815 patent/US8945591B2/en not_active Expired - Fee Related
-
2014
- 2014-12-30 US US14/585,740 patent/US9492537B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3906092A (en) * | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
| WO1990014424A1 (en) * | 1989-05-16 | 1990-11-29 | Scripps Clinic And Research Foundation | Method for isolating receptors having a preselected specificity |
| WO1992011389A1 (en) * | 1990-12-21 | 1992-07-09 | F. Hoffmann-La Roche Ag | Hla dqbeta dna typing |
| US5691136A (en) * | 1991-10-23 | 1997-11-25 | Baylor College Of Medicine | Fingerprinting bacterial strains using repetitive DNA sequence amplification |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1434723A (zh) | 免疫刺激性寡脱氧核苷酸 | |
| CN1248736C (zh) | 疫苗组合物 | |
| US7858588B2 (en) | Immunostimulatory oligodeoxynucleic molecules | |
| CN1753687A (zh) | Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用 | |
| AU784403B2 (en) | Pharmaceutical composition for immunomodulation and preparation of vaccines comprising an antigen and an immunogenic oligodeoxynucleotide and a polycationic polymer as adjuvants | |
| ZA200209479B (en) | Immunostimulatory oligodeoxynucleotides. | |
| AU2001281812A1 (en) | Immunostimulatory oligodeoxynucleotides | |
| AU2002320762A1 (en) | Immunostimulatory oligodeoxynucleic molecules | |
| CN101052643A (zh) | 抑制先天免疫应答和自身免疫的方法和组合物 | |
| CN1918293A (zh) | 用于对人及高等动物进行治疗性和预防性免疫刺激的取代的非编码核酸分子 | |
| CN1771054A (zh) | 改进的疫苗 | |
| HK1056678B (zh) | 免疫刺激性寡脱氧核苷酸 | |
| CN1688192A (zh) | 免疫刺激核酸 | |
| CN1852917A (zh) | 使用免疫刺激性寡核苷酸和/或免疫子化合物结合细胞因子和/或化疗剂或放射治疗对免疫系统的协同刺激作用 | |
| HK1069187A (en) | Method for stabilising of nucleic acids | |
| HK1100824A (en) | Substituted, non-coding nucleic acid molecule for therapeutic and prophylactic stimulation of the immune system in humans and higher animals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: INTSEL STOCK CO., LTD. Free format text: FORMER NAME OR ADDRESS: CISTEM BIOTECHNOLOGIES GMBH |
|
| CP01 | Change in the name or title of a patent holder |
Address after: Austria Vienna Patentee after: INTERCELL AG Address before: Austria Vienna Patentee before: Intersell Biomedical Research and Development Corp. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee |
Owner name: VALNEVA AUSTRIA GMBH Free format text: FORMER NAME: INTERCELL AG |
|
| CP01 | Change in the name or title of a patent holder |
Address after: Austria Vienna Patentee after: Austria Co.,Ltd. Address before: Austria Vienna Patentee before: Intel Searl Austria AG |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140320 Address after: Austria Vienna Patentee after: Intel Searl Austria AG Address before: Austria Vienna Patentee before: Intercell AG |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20070411 |